Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Vocci, F. J. Articles by Elkashef, A. Search for Related Content PubMed Citation Articles by Vocci, F. J. Articles by Elkashef, A. Opioids Stress Behavior Therapy Cognitive Therapy Psychodynamic Therapy Cocaine Other Somatic Therapy

Medication Development for Addictive Disorders: The State of the Science

In 1989, the National Institute on Drug Abuse (NIDA) established its Medications Development Program. This program has concentrated on developing pharmacotherapies for opiate and cocaine dependence and, more recently, for methamphetamine and cannabis dependence. The major goals of this program are to optimize existing treatments and to expand treatment options for physicians and patients. This review will concentrate on the development of pharmacotherapies for the following substance abuse disorders: opiate, cocaine, methamphetamine, and cannabis dependence. Left untreated, opiate and stimulant dependence are responsible for significant morbidity and mortality. For example, use of illicit opiates is associated with an increased risk of hepatitis C infection, HIV infection, and other medical consequences, e.g., an overdose. The NIDA Medications Development Program has had success in developing, with pharmaceutical partners, levomethadyl acetate, buprenorphine, and buprenorphine/naloxone for opiate dependence. Moreover, several marketed medications have shown promise in reducing cocaine use. Of interest, these medications likely operate through diverse neurochemical mechanisms, suggesting that combination therapy may be a rational next step that could increase treatment gains further in cocaine-dependent patients. The Medications Development Program has also identified multiple neuronal mechanisms that are altered by chronic administration of drugs of abuse. Advances in neuroscience have identified changes in conditioned cueing, drug priming, stress-induced increases in drug intake, and reduced frontal inhibitory mechanisms as all being possible for the development of, maintenance of, and possible relapse to, addiction. Potential medications that modulate these mechanisms are highlighted.

This article has been cited by other articles:

				J. L. Martelle, R. Claytor, J. T. Ross, B. A. Reboussin, A. H. Newman, and M. A. Nader Effects of Two Novel D3-Selective Compounds, NGB 2904 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the Reinforcing and Discriminative Stimulus Effects of Cocaine in Rhesus Monkeys J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 573 - 582. [Abstract] [Full Text] [PDF]

				S. S. Negus, N. K. Mello, B. E. Blough, M. H. Baumann, and R. B. Rothman Monoamine Releasers with Varying Selectivity for Dopamine/Norepinephrine versus Serotonin Release as Candidate "Agonist" Medications for Cocaine Dependence: Studies in Assays of Cocaine Discrimination and Cocaine Self-Administration in Rhesus Monkeys J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 627 - 636. [Abstract] [Full Text] [PDF]

				M.-C. Ko, L. D. Bowen, D. Narasimhan, A. A. Berlin, N. W. Lukacs, R. K. Sunahara, Z. D. Cooper, and J. H. Woods Cocaine Esterase: Interactions with Cocaine and Immune Responses in Mice J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 926 - 933. [Abstract] [Full Text] [PDF]

				R. N. Pechnick, S. Glasner-Edwards, M. Hrymoc, and J. N. Wilkins Preclinical Development and Clinical Implementation of Treatments for Substance Abuse Disorders Focus, January 1, 2007; 5(2): 151 - 162. [Abstract] [Full Text] [PDF]

				Bibliography for Substance Abuse: Diagnosis and Treatment Focus, January 1, 2007; 5(2): 184 - 186. [Full Text] [PDF]

				D. Gonzales, S. I. Rennard, M. Nides, C. Oncken, S. Azoulay, C. B. Billing, E. J. Watsky, J. Gong, K. E. Williams, K. R. Reeves, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA, July 5, 2006; 296(1): 47 - 55. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us